Physician profile
Laura Hallak
NPI 1861609778
$1,631.10
in general payments reported to CMS, 2019-2025
16 companies · $262 in 2025
The $262 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $15.45 · 2022: $40.42 · 2023: $316 · 2024: $998 · 2025: $262.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,575.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,575.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $321.27 | 2023-2025 | Repatha, Otezla, Otezla |
| Astrazeneca Pharmaceuticals Lp | $258.27 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $207.50 | 2022-2024 | |
| Lilly USA, LLC | $170.66 | 2023-2024 | Mounjaro, Zepbound, Trulicity |
| Novo Nordisk INC | $163.95 | 2023-2025 | Ozempic, Wegovy, Rybelsus |
| Pfizer INC. | $158.13 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $109.03 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.96 | 2024-2025 | Jardiance |
| Phathom Pharmaceuticals, INC. | $40.11 | 2024 | Voquezna |
| Glaxosmithkline, LLC. | $27.54 | 2024 | Arexvy, Trelegy Ellipta |
| Janssen Pharmaceuticals, INC | $26.35 | 2023 | Xarelto |
| Dexcom, INC. | $25.45 | 2024 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $23.98 | 2024 | Cologuard Collection Kit |
| Abbott Laboratories | $19.96 | 2024 | Freestyle Libre 3 |
| Hologic Sales and Service, LLC | $19.74 | 2023 | Aptima |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.20 | 2025 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Hallak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.